Treatment withdrawal · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine showed no clear difference in treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Brivaracetam showed no clear difference in treatment withdrawal compared with placebo (low certainty).
1 finding from 1 review
Treatment withdrawal · adults (aged 16 years and over) with drug‐resistant epilepsy
It is very uncertain whether ketogenic diet (KD) changes treatment withdrawal compared with usual care (very low certainty).
1 finding from 1 review
Treatment withdrawal · children (aged 1 to 18 years) with drug‐resistant epilepsy
Ketogenic diet (KD) showed no clear difference in treatment withdrawal compared with usual care (low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant generalised tonic‐clonic seizures
It is very uncertain whether add‐on lamotrigine changes treatment withdrawal compared with placebo (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Rufinamide probably leads to higher treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Oxcarbazepine probably leads to higher treatment withdrawal compared with control (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Topiramate leads to higher treatment withdrawal compared with placebo (high certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Tiagabine probably leads to higher treatment withdrawal compared with placebo control (moderate certainty).
1 finding from 1 review
Treatment withdrawal · patients with drug‐resistant epilepsy
1 finding from 1 review
Treatment withdrawalNumber of participants withdrawn for any reason · people with drug‐resistant focal epilepsy
Gabapentin showed no clear difference in treatment withdrawalNumber of participants withdrawn for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawal rates ‐ Any dose · people with drug‐resistant focal epilepsy
Levetiracetam showed no clear difference in treatment withdrawal– all doses compared with placebo (high certainty).
1 finding from 1 review
Intervention not reported
Treatment withdrawal (any reason) · people with drug‐resistant focal epilepsy
The intervention showed no clear difference in treatment withdrawal (any reason) (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Pregabalin showed no clear difference in treatment withdrawal for any reason compared with active comparators (low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Pregabalin probably leads to higher treatment withdrawal for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Treatment withdrawal (adverse effect) · people with drug‐resistant focal epilepsy
The intervention probably leads to higher treatment withdrawal (adverse effect) (moderate certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · people (aged 12 years and over) with drug‐resistant focal epilepsy
Perampanel add‐on may leads to higher treatment withdrawal due to any reason compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
1 finding from 1 review